Apollomics Inc. Class A Ordinary Shares

Apollomics Inc. a biotechnology company engages in the discovery and development of oncology therapies to address unmet medical needs in California Hangzhou Shanghai China and Australia. It develops APL-101 (Vebreltinib) a potent selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active small molecule multiple tyrosine kinase inhibitor for liver cancer breast cancer and esophageal cancer; and APL-122 a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals Inc. and changed its name to Apollomics Inc. in January 2019. Apollomics Inc. was incorporated in 2015 and is based in Foster City California.